Frederic Triebel News Today

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49...

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur...

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care... | March 31, 2023

Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen...

- Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer - Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 /... | August 1, 2022

(RTTNews) - Immutep Limited (IMMP) reported new interim data from 2nd line NSCLC patients in the phase II TACTI-002 trial. This part of TACTI-002 ...

TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducte

TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in...

ScoPo’s Powerplays: Health stocks tumble but half-price sale presents buying opportunities